Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
17.59
+0.42 (2.45%)
At close: Oct 9, 2026, 4:00 PM EDT
17.55
-0.04 (-0.23%)
After-hours: Oct 9, 2026, 7:58 PM EDT
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
265
Market Cap
14.07B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.60B |
| BioMarin Pharmaceutical | 3.41B |
| Exelixis | 2.44B |
| Halozyme Therapeutics | 1.66B |
| Madrigal Pharmaceuticals | 1.28B |
| Bio-Techne | 1.22B |
| Ascendis Pharma | 1.20B |
| Corcept Therapeutics | 830.81M |
SMMT News
- 5 days ago - Summit Therapeutics Proxy statement: Proxy filing - Filings
- 6 days ago - AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics - Business Wire
- 9 days ago - Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types - Business Wire
- 9 days ago - Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway - Business Wire
- 12 days ago - Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals - Invezz
- 12 days ago - AMD, Nvidia, Navitas, Summit Therapeutics, Fair Isaac, and More Stocks That Explain Today's Market - Barrons
- 13 days ago - AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs - WSJ
- 13 days ago - AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - Reuters